SPDR Advertisement SureTrader SureTrader SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, LODE MAKING ME RICH, homeslice10, lasers, AyeEye
Search This Board:
Last Post: 7/6/2015 1:42:13 AM - Followers: 643 - Board type: Free - Posts Today: 3


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 


Press Releases

 

 

 

 



 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#85781  Sticky Note OCAT has been added to 3 Russell indices AyeEye 06/26/15 06:12:35 PM
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#86060   Like what Lazers said $OCAT chuckanutman 07/06/15 01:42:13 AM
#86059   I think it's very fair and constructive to farviewhill 07/06/15 12:58:54 AM
#86057   The main point is that imo basing one's elysse1kittycat 07/05/15 10:33:10 PM
#86056   CPA's from Arthur Anderson acted as Corporate Prostitutes AyeEye 07/05/15 10:28:25 PM
#86055   Lots of folks "followed the money" with Enron-how elysse1kittycat 07/05/15 08:07:07 PM
#86054   OCAT has alot going on with many possibilities chuckanutman 07/05/15 07:47:49 PM
#86052   Quote LOL, "By publicly declaring its +$5 mil Captain Kirk 07/05/15 06:54:37 PM
#86051   "Follow the Money" $OCAT Investment! lasers 07/05/15 06:08:17 PM
#86050   Regenerative medicine's big bet: Putting an end to lasers 07/05/15 06:04:56 PM
#86045   Regenerative medicine's big bet: Putting an end to calm61 07/05/15 04:28:08 PM
#86042   I used the word "delusional" earlier today and elysse1kittycat 07/04/15 11:41:36 PM
#86040   I've been posting that same thing for a farviewhill 07/04/15 09:36:28 PM
#86038   I think it was one of your posts farviewhill 07/04/15 09:22:31 PM
#86037   Also, the same Board that allowed rabin to farviewhill 07/04/15 09:04:56 PM
#86034   Exactly , this company has no idea when fulleroots 07/04/15 08:24:22 PM
#86033   Not everyone agrees-this form of recent analysis rates elysse1kittycat 07/04/15 05:20:57 PM
#86032   Excellent! lasers 07/04/15 04:21:43 PM
#86031   stemdynasty stated something interesting about OCAT. chuckanutman 07/04/15 04:12:23 PM
#86030   OCAT has purpose to succeed in the endeavor chuckanutman 07/04/15 02:58:25 PM
#86027   It does matter if you are creating an elysse1kittycat 07/04/15 12:29:24 PM
#86026   It does matter if you are creating an chuckanutman 07/04/15 12:19:40 PM
#86025   It doesn't matter whether Rabin was temporary or not. elysse1kittycat 07/04/15 12:17:09 PM
#86024   Rabin steppped in as a temporary replacement for chuckanutman 07/04/15 12:13:26 PM
#86023   The time it took to replace Rabin means nothing. elysse1kittycat 07/04/15 12:06:33 PM
#86022   What damage can you create by untruth when chuckanutman 07/04/15 11:58:06 AM
#86021   I agree again on all counts. elysse1kittycat 07/04/15 11:47:47 AM
#86019   For all you know he may even have mind1 07/04/15 11:34:20 AM
#86018   I was actually pretty optimistic about this company elysse1kittycat 07/04/15 11:28:24 AM
#86017   Quote: Bombs-bursting in air over poultry standards and limiting-poultry-social elysse1kittycat 07/04/15 11:26:01 AM
#86016   Agree, I always say expect the worst, you mind1 07/04/15 11:05:54 AM
#86015   Another great point-historically speaking when something has been elysse1kittycat 07/04/15 11:03:00 AM
#86014   There is one other item that makes we mind1 07/04/15 10:54:01 AM
#86013   Bombs-bursting in air over poultry standards and limiting-poultry-social-expressions. chuckanutman 07/04/15 10:52:24 AM
#86012   Great point. elysse1kittycat 07/04/15 10:31:51 AM
#86011   SABRIENT gave OCAT a "BUY RATING" chuckanutman 07/04/15 10:20:21 AM
#86010   Even in his PR statement he makes no mind1 07/04/15 10:14:27 AM
#86009   All I know is that I have no elysse1kittycat 07/04/15 10:10:11 AM
#86008   Blackrock is a well known investment firm with lasers 07/04/15 06:36:41 AM
#86007   Lol i wonder what that new hire is fulleroots 07/04/15 04:29:21 AM
#86006   OCAT large share holder BlackRock Fund Advisors was AyeEye 07/03/15 11:23:58 PM
#86005   Maybe a surprize OCAT partnership with the platelet chuckanutman 07/03/15 07:10:12 PM
#86004   I agree with you, and imo it is elysse1kittycat 07/03/15 05:23:22 PM
#86003   Something telling me this was the 10 million King215grill 07/03/15 04:24:12 PM
#86002   They may be able to short anywhere above King215grill 07/03/15 04:12:16 PM
#86001   As well as a huge guess as to farviewhill 07/03/15 04:05:36 PM
#86000   Lasers: Thank You! King215grill 07/03/15 03:47:24 PM
#85999   Thanks mind1 07/03/15 03:08:27 PM
#85998   What we have is accompanying info on the lasers 07/03/15 03:03:51 PM
#85997   Sounds like the turnaround has started. elllk 07/03/15 02:59:45 PM
#85996   There is joy in Ocataville today as the elysse1kittycat 07/03/15 02:53:50 PM
PostSubject